Omniscan (Gadodiamide)

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of anatomical structures and pathological changes.

• Central nervous system imaging: enhances detection of lesions, tumors, and vascular malformations.
• Cardiovascular imaging: improves delineation of cardiac chambers, vessels, and myocardial perfusion.
• Whole‑body and oncologic imaging: aids in identifying metastatic disease and assessing tumor vascularity.

• Gadodiamide is a low‑molecular‑weight, non‑ionic gadolinium chelate that distributes in the extracellular fluid after intravenous injection. It shortens T1 relaxation times of nearby water protons, producing a bright signal on T1‑weighted MRI sequences and thereby increasing contrast between normal and abnormal tissues.

Adverse reactions to gadodiamide‑based contrast agents are generally uncommon but can range from mild to severe.

Common Side Effects

• Nausea: mild, transient discomfort.
• Headache: short‑lasting headache after injection.
• Warmth or flushing: sensation of warmth at the injection site.
• Metallic taste: brief metallic sensation in the mouth.
• Injection site pain: mild discomfort at the site of administration.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
• Anaphylactoid reactions: hives, bronchospasm, or hypotension.
• Severe allergic reaction: angio‑edema or anaphylaxis.
• Cardiac arrest: rare but life‑threatening event.
• Renal toxicity: worsening of kidney function in susceptible individuals.

When using Omniscan, clinicians should assess patient risk factors and monitor for adverse events.

• Renal function assessment: evaluate glomerular filtration rate before administration.
• Pregnancy caution: avoid use unless clearly needed, as safety data are limited.
• Breastfeeding guidance: consider discontinuing breastfeeding for 24‑48 hours after injection.
• Allergy history: screen for prior reactions to gadolinium‑based agents.
• Hydration encouragement: ensure adequate fluid intake post‑procedure to aid elimination.
• Store at ambient temperature: keep in original packaging, protect from light and moisture.

Gadodiamide may interact with other agents that affect renal function or cause hypersensitivity.

Major Interactions (Avoid)

• Loop diuretics: may exacerbate renal impairment, increasing NSF risk.
• High‑dose intravenous iron: can compete for plasma protein binding sites.

Moderate Interactions (Monitor Closely)

• Nephrotoxic antibiotics (e.g., aminoglycosides): require renal function monitoring.
• Other contrast media: cumulative gadolinium exposure may raise NSF risk.
• Antihistamines: may mask early signs of an allergic reaction.
• Steroids: may alter immune response to the agent.